About
Pricing
FAQs
Providers
Trials
Blog
Login
Get started
Finding studies
Search
Narrow
Order
Status
Recruiting
Not yet recruiting
Active, not recruiting
Enrolling by invitation
Completed
Terminated
Phase
Early phase 1
Phase 1
Phase 1–2
Phase 2
Phase 2–3
Phase 3
Phase 4
No phase
Who can join
Healthy volunteers too
Searching
1–20 of 2,640
Completed
Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C
The purposes of the PLUS study were to confirm the safety and tolerability of two doses of LocteronTM (320 ug and 640 ug) dosed over four weeks in patients who had failed prior…
NCT00593151
·
Detroit, Michigan and 4 others
Completed
An Observational Study to Assess the Effect of Cumulative Ribavirin Dose in Participants With Chronic Hepatitis C
The purpose of this open-label, non-randomized, single-arm, multicentre observational study is to investigate the influence of the cumulative dose (total administered dose/…
NCT02557646
·
Ajka and 26 others
Completed
Radiolabel ADME (Absorption, Distribution, Metabolism, and Excretion) Study Of [14C] PF-00868554 In Healthy Adult Male Subjects
This is a phase 1 study to assess the routes of elimination of a single oral dose of \[14C\] PF-00868554 and to characterize the metabolic profile following single dose…
NCT00823745
·
Tacoma, Washington
Completed
Health and Migration Trajectories of Housekeepers in Bamako
In Mali, migration from rural zones is a cultural phenomenon existing since 1970.
NCT05472051
·
Bamako, Niamakoro, Sièbougouni, Rue 173, Porte 146
Completed
Brief Intervention for Rural Women at High Risk for HIV/HCV
The overall aim of this study is to reduce risk behaviors and increase health and behavioral health service utilization among disadvantaged, drug-using rural women at high risk…
NCT01840722
·
Hazard, Kentucky
Unknown
HRN 004- Peginterferon a-2a Plus Ribavirin for Chronic Hepatitis C Infection in HIV Infected Persons Who Have Failed to Achieve a Sustained Virologic Response Following Previous Interferon Therapy
Objectives: Primary To evaluate the safety, tolerability, and efficacy of Peginterferon a-2a plus Ribavirin for the treatment of chronic hepatitis C (CHC) infection in persons…
NCT00215839
·
New York, New York
Completed
Evaluation of Treatment of Chronic HCV Patients in Chronic Kidney Disease Versus End Stage Renal Disease Patients
1. To asses curability of( Ombitasvir ,Paritaprevir,Ritonavir) in chronic HCV infected patients in those with CKD versus ESRD in Assiut Hospital University .
NCT03341988
·
Asyut
Completed
Macrophages, Portal Hypertension, and Liver Function During AbbVie Treatment of Chronic Hepatitis C
Investigation of the effects of the new Abbvie direct acting anti-viral (DAA) treatment of chronic viral hepatitis C infection on the macrophage specific activation marker soluble…
NCT02526641
·
Aarhus
Completed
Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients
Participants with genotype 1 HCV infection were randomized to 1 of 3 sofosbuvir doses (100 mg, 200 mg, or 400 mg) or matching placebo once daily based upon stratification for…
NCT01054729
·
San Francisco, California and 6 others
Completed
Post-marketing Surveillance of HIV-infected Patients With Chronic Hepatitis C Treated With PegIntron Pen and Rebetol (Study P04584)
The objective of the study was to assess the safety and efficacy of peginterferon alfa-2b (PEG-IFN alfa-2b) and ribavirin (RBV) administered to participants coinfected with Human…
NCT00736242
Completed
Effect of Teleprevir in Triple Therapy on Intrahepatic Immunological Mechanisms
Chronic hepatitis C infection (HCV) is a disease that affects worldwide about 170 million people.
NCT01641094
·
Delft, South Holland and 1 other
Completed
Utility of MicroRNAs for Diagnosing Hepatocellular Carcinoma in Hepatitis C Patients
This study evaluates a target population of patients with Hepatitis C virus (HCV) infection, including those with complications like liver cirrhosis (LC) and hepatocellular…
NCT07404566
·
Alexandria, El Alexandria
Withdrawn
Safety and Tolerability of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for the Treatment of Vietnamese Subjects With Chronic Hepatitis C Genotype 1 (P08599)
This study is designed to assess the safety and tolerability of boceprevir dosed 800 mg three times daily (TID) orally (PO) in combination with Peginterferon alfa-2b (PEG2b) 1.5…
NCT01641666
Terminated
Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303)
This is a Phase 3b/4, prospective, open-label, randomized, multicenter study of peginterferon alfa-2b plus ribavirin in participants with chronic hepatitis C, genotype 1.
NCT00493805
Completed
Identification to Elimination in HCV-Infected Individuals
Approximately 3.5 - 5 million Americans are living with hepatitis C virus (HCV) in the United States. HCV significantly impacts rural Pennsylvania.
NCT03195205
·
DuBois, Pennsylvania
Unknown
Safety and Efficacy of Grazoprevir and Elbasvir for GT1ang GT6 With and Without HIV
This study will evaluate the safety and efficacy of combination treatment with grazoprevir + elbasvir for compensated cirrhotic participants with chronic genotype 1 (GT1) and…
NCT03037151
·
Bangkok and 1 other
Completed
Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir
1. The primary objective is to study the comparative effectiveness and tolerability of boceprevir vs. telaprevir in HCV treatment, within the VA population.
NCT02113631
·
Cleveland, Ohio
Completed
Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual
Patients with chronic hepatitis genotype 1b, who are intolerant or ineligible to Interferon alfa therapy with or without Ribavirin, will be treated for 24 weeks with Daclatasvir…
NCT01995266
·
Beijing, Beijing Municipality and 37 others
Unknown
4-Methylumbelliferone as a Treatment for Chronic HBV/HCV
Open-label studies, anecdotal reports, and in vitro scientific research indicate that 4-methylumbelliferone (active ingredient of the dietary supplement Heparvit®) may prevent and…
NCT00225537
·
San Antonio, Texas
Recruiting
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
This is a double-blind, phase 2 study to evaluate safety and efficacy of rosuvastatin in comparison to placebo after 2 years in patients with compensated cirrhosis.
NCT05832229
·
La Jolla, California and 12 others
Back
1
2
3
···
132
1 / 132
Next
Data from
ClinicalTrials.gov
Terms
